Friday, 16 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 22, 2026

P&G Announces Fiscal Year 2026 Second Quarter Results

View original at finance.yahoo.com
P&G Announces Fiscal Year 2026 Second Quarter Results Net Sales +1%; Organic Sales 0% Diluted EPS $1.78, -5%; Core EPS $1.88, 0% UPDATES GAAP EPS FOR RESTRUCTURING OUTLOOK MAINTAINS FISCAL YEAR SALES, CORE EPS GROWTH AND CASH RETURN GUIDANCE CINCINNATI, January 22, 2026--(BUSINESS WIRE)--The Procter & Gamble Company (N…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • FX expected to provide $200M after-tax tailwind for FY2026

    80% confidence
  • P&G has confidence in plans to deliver stronger results in the second half of fiscal year 2026

    80% confidence
  • FY2026 diluted EPS growth revised down to +1% to +6% (from +3% to +9%) due to restructuring charges

    80% confidence
  • P&G's Q2 results keep the company on track to deliver within fiscal year guidance ranges for organic sales growth, core EPS growth and adjusted free cash flow productivity in a challenging consumer and geopolitical environment

    80% confidence
  • FY2026 organic sales growth guidance maintained at 0% to +4%

    80% confidence
  • P&G's strategy is to reinvent P&G and create the CPG company of the future, delivering long-term balanced top- and bottom-line growth

    80% confidence
  • Tariff costs expected to create $400M after-tax headwind for FY2026

    80% confidence
  • Commodity costs expected to be neutral for FY2026 (updated from prior forecast)

    80% confidence
  • FY2026 core EPS growth guidance maintained at 0% to +4% (range $6.83 to $7.09)

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com